KFF: ACA significantly narrowed disparities in coverage for people of color—but those trends may be reversing

FierceHealthcare | February 18, 2019

The implementation of the Affordable Care Act (ACA) has significantly narrowed the disparities in coverage experienced by people of color, but those gains may be slowing, according to a new report. A new brief from the Kaiser Family Foundation looks at the disparity in health coverage by race and ethnicity between 2013 and 2017 using American Community Survey data. In 2013, 16.8% of the nonelderly population lacked insurance, with the scales tipping higher for people of color, KFF found. After the ACA coverage expansion in 2014, the Hispanic population experienced the largest coverage gain, followed by Asians, American Indians and Alaskan Natives (AIAN) and blacks, compared to whites.

Spotlight

A nurse eases a pre-op patient worried about HAIs and antibiotic resistance in this 360 video dramatization of Clorox Healthcare™ Nasal Antiseptic Swabs, a povidone-iodine alternative to antibiotics for nasal decolonization.


Other News
FUTURE OF HEALTHCARE

Athlete Training and Health Expands with New Facilities, Team Members

Athlete | September 27, 2022

Whether for active adults or Olympians, Athlete Training and Health (ATH) encourages its athletes to strive for their own personal best. ATH is raising its own bar on community health and performance training once again, with the announcement of two new facilities in the Houston area and the addition of another world-renowned coach to its executive staff. “What we know is that evidence-led training allows everyone to benefit from the science behind the best in health and performance. Expanding and offering this world-class environment and approach will benefit athletes of all ages and abilities. We are pleased to collaborate with healthcare systems, professional sports teams, universities and school districts to continue pursuing a new level of health and performance training for many communities.” Greg Centilli, chief operating officer for ATH and a recent addition to the growing ATH organization Construction has begun on a new ATH sports medicine and human performance facility in Pearland. Located on the Memorial Hermann Pearland Hospital campus at 16100 South Freeway, the roughly 13K-square-foot facility will house unparalleled human performance expertise and opportunities to train in an adult fitness space, a professional sport-style weight room, and on indoor and outdoor turf fields. The facility, a collaboration between ATH, Memorial Hermann and UT Physicians Orthopedics, is expected to open fall 2023. Also in the works is an ATH facility in Cypress, also in collaboration with Memorial Hermann. On the campus of Memorial Hermann Cypress Hospital at 27800 Highway 290, ATH will open and operate a roughly 13K-square-foot facility in 2024. At this location, student, collegiate, professional and adult athletes will find the expertise needed to up their game on their own performance. “We are extremely pleased to welcome Professor Cronin to ATH. His science-based expertise and educational experience, alongside his international standing, will help educate investors and the general markets on the significance and industry importance of ATH-led initiatives,” said Centilli. Cronin serves as professor of strength and conditioning at the Sports Performance Research Institute of New Zealand (SPRINZ) at Auckland University of Technology (AUT). His research interests are in human movement, particularly around strengthening of muscle, injury resistance, return to play and high-performance sports. Cronin’s research has been published in more than 400 peer-reviewed papers. AUT and ATH have a long-standing history. Post-graduate fellows from AUT conduct research at ATH as part of a team involving coaches and select students, as well as collaborate on sport technology development. “I know the organization well, and my research interests and expertise align well with ATH’s interest in sporting performance and allied health, so I’m very excited to be advising ATH about the latest science-based studies and learnings to support their people, programs and products,” Cronin said. Celebrating Wins While its clients celebrate personal victories, ATH celebrates industry wins. Readers of Living Magazine recently voted ATH the “2022 Best Health Club/Gym” winner in McKinney/Allen and in Katy/Fulshear via an annual award competition that allows readers to nominate and then vote for their favorite companies by category and market. ATH also was honored to be named a “2022 Neighborhood Favorite” in NextDoor’s annual celebration of local businesses, and a finalist for “2022 Best Gym/Fitness Center in Houston” by readers of Houston Chronicle in an annual awards competition voted on by Houstonians. “While it’s important for us to acknowledge the hard work of our coaches and staff who make awards like these possible, it’s our job to continuously raise the bar, so we consider this just the beginning,” noted Centilli. “We are excited about what we have accomplished and are even more excited for the developments ahead.” Whether it’s losing the pandemic pounds, living in a healthier body, or even reaching the pinnacle of your sport, the certified, experienced sports performance experts at ATH have the expertise and a program tailored just for you. ABOUT ATHLETE TRAINING AND HEALTH (ATH) ATH is more than a gym. It’s a place of community, inspiration and results. ATH provides award-winning adult fitness and sports performance training for youth, collegiate and professional athletes. ATH utilizes best practices from human performance research to provide a world-class training environment for athletes and adults of all fitness levels collaborating with hospitals, professional sports teams, universities and school districts to set new standards for health and performance training. ATH invests heavily in the post-graduate education of its performance coaches, who in turn develop evidence-led training programs guaranteed to deliver sustainable results. ATH currently operates two training centers in the Houston metro area and one in Allen, north of DFW.

Read More

HEALTH TECHNOLOGY

Base Business Solutions and Uniphore Partner to Bring Emerging Technology to Vietnam’s CX Industry

Uniphore | September 12, 2022

Base Business Solutions a leading provider of cloud and hosted customer experience and contact center solutions in Vietnam announced it has entered into a strategic partnership with Uniphore, the leader in Conversational AI and Automation. Through this partnership, BaseBS will be well positioned to enhance customer experiences, improve employee performance, and better understand customer insights to achieve superior business outcomes. As part of the agreement, BaseBS will offer customers Conversational AI and Automation capabilities across their initiatives around self-service and assisted service channels. Uniphore’s X platform is an integrated conversational AI and automation platform that combines automatic speech recognition (ASR) including the Vietnamese language, natural language processing (NLP), robotic process automation (RPA), emotion AI and knowledge AI that enterprises need in today’s tech-savvy customer era. These technology components translate into specific offerings for customers in the form of chatbots, voice bots, conversational analytics for quality automation, and customer analysis and agent guidance in real-time. The partnership will have far-reaching benefits for customers, employees, and organizations that will impact not only how they do business today as they continue to adjust to the current global situation, but also in the long term. Benefits include Personalized automated resolutions for customers thus bringing in time to value through Uniphore’s U Self Serve product Contact center employee productivity and efficiency will see a boost through U-Assist, a Uniphore product that can guide agents in real-time with in-call alerts, next-best-action and reduce their after-call work Businesses will be able to make data-driven decisions with smarter conversational analytics. Through Uniphore’s U Analyze solution, businesses can transform CX by analysing conversations from across platforms including voice, email, and text to increase effectiveness with omnichannel support and an integrated view of conversations to discover customers' intent and sentiments “BaseBS is extremely pleased to partner with Uniphore on our journey to bring emerging technology such as Artificial Intelligence (AI), machine learning and automation to the CX industry in Vietnam. With Uniphore’s conversational AI and automation platform we will be better positioned to enable our customers to personalize conversations, enhance contact center employee productivity and use conversation insights for better decisions.” Mr. Pham Xuan Phuc, Vice President, Base Business Solutions “We are excited about the partnership with BaseBS as they look ahead to strengthen and offer more comprehensive CX solutions for contact centers in the local market,” said Mr. Gokul Gopalakrishnan, Senior Vice President & Business Head, Asia, Uniphore. “We see a natural synergy with BaseBS thereby creating strong joint value propositions, go-to-market strategies, and unmatched CX solutions for enterprises, and experiences for customers.” BaseBS is part of Uniphore’s Reseller partner program. The program provides partners with the necessary resources to leverage cutting-edge technology and enhance their portfolio and offerings resulting in increased revenue growth. Uniphore also launched the Unite App Alliance Partner Program, which enables value-driven collaboration and cross-selling for participating Independent Software Vendors (ISV) to have greater access to and involvement in shaping the direction and strategy of tomorrow’s conversational AI and automation, and supporting CX technology innovation. About Uniphore Uniphore is the global leader in Conversational Automation. Every day, billions of conversations take place across industries — customer service, sales, HR, education and more. Whether they are human to human, human to machine or machine to machine, conversations are at the heart of everything we do, and the new currency of the enterprise. At Uniphore, we believe companies that best understand and take action on those conversations will win. We have built the most comprehensive and powerful conversational automation platform that combines conversational AI, workflow automation and RPA (Robotic Process Automation) with a business user friendly UX in a single integrated platform to transform and democratize customer experiences across industries. Follow our blog and connect with us on LinkedIn, Twitter, Facebook, and Instagram. About Base Business Solutions Founded in 2005, BaseBS is one of the leading companies providing cloud and hosted customer experience and contact center solutions in Vietnam. BaseBS offers tailor-made CX solutions to hyper-scale and large enterprise clients that empower them to achieve customer service excellence and gain competitive advantages in the market. We are honored as Advanced Technology Partner of Cisco in implementing Call Center & Contact Center infrastructure. A combination of comprehensive industry expertise, a professional team and leading-edge technologies enables our clients to modernize their customer journey and maximize business productivity. Our portfolio is active in a wide range of business areas such as Banking & Finance, Insurance, Retail, Logistics, Hospitality, Medical & Healthcare, etc.

Read More

HEALTH TECHNOLOGY

Alexandra Clyde appointed to Sequana Medical Board of Directors

Sequana Medical NV | August 29, 2022

Sequana Medical NV a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive with an exceptional understanding and track record of successfully navigating health economics and reimbursement in the medical device industry. The Company also announces that Erik Amble will step down as a member of the Board of Directors after the board meeting of 7 September 2022, and will continue to attend the meetings as a board observer in a non-voting capacity. “Alex will be a critical member of our Board as Sequana Medical prepares to expand commercialization of the alfapump. Her experience from more than 25 years at Medtronic, a global leader in healthcare technology, and her understanding of healthcare systems around the world will prove invaluable as we continue to grow our business and seek to transform the care of liver disease and heart failure. On behalf of the Board, I would also like to thank Erik for his tremendous contributions to the Company and we are pleased to still have him as an observer on the Board.” Pierre Chauvineau, Chairman of the Board at Sequana Medical Ms. Clyde added: “I believe that both of Sequana Medical’s programs – the alfapump® and DSR® therapy – have the potential to deliver tremendous benefit to patients and the healthcare community. In these two large and growing patient populations, liver disease and heart failure, drug-resistant fluid overload is a significant and burdensome challenge with limited effective treatment options. Sequana Medical is in an exciting position to help these patients and reduce the burden of disease. I look forward to working with the Board and management team to help the Company reach its potential.” Mr. Amble added: “At this time in the Company’s evolution, it is critically important that the Board brings expertise to help guide the Company’s commercial readiness activities in North America. With Doug and Alex now on the Board, I am confident that the Board is well positioned to guide Sequana Medical as it enters a period of potential exponential growth. It’s been a pleasure to work with Sequana Medical’s Board and management team for more than 15 years and I look forward to continuing my involvement as a Board observer.” Ms. Clyde is Senior Vice President of Global Health Economics, Policy, and Reimbursement for Medtronic plc. In this role, she leads a global function of more than 300 reimbursement and health economics professionals and provides company-wide leadership on health and payment policy. She is a member of the Duke Margolis Value-Based Payment and Innovative Technology Consortium, the Health Technology Assessment International (HTAi) Policy Forum, and the Advisory Board for the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. She is a former member of the Health Care Payment Learning and Action Network’s Guiding Committee which is charged by the US Secretary of Health and Human Services with accelerating the health care system’s transition to alternative payment models (APMs) by combining the innovation, power, and reach of the public and private sectors. She has also participated in various Centers for Medicare and Medicaid Services technical advisory councils as well as other private and public sector initiatives to improve value in health care. Alex graduated from Colgate University with a B.A. in Economics and from Harvard University with a M.S. in Health Policy and Management. Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.

Read More

HEALTH TECHNOLOGY

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide. Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths. ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S. "We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world." Dr. Bo Shan, Antengene's Chief Scientific Officer About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.

Read More